These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38687948)

  • 1. Local therapy combined with anti-PD-1 immunotherapy for advanced lung adenocarcinoma: A case report.
    Wu N; Yang X; Zhai Y; Lu W
    J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Good response of cadonilimab (PD-1/CTLA-4 bi-specific antibody) to patients with advanced lung adenocarcinoma after immunotherapy resistance: A case report.
    An E; Lu J; Chen L
    Asian J Surg; 2024 Jul; 47(7):3348-3349. PubMed ID: 38609824
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
    Tang Y; Li Y; Zhang L; Tong G; Ou Z; Wang Z; Zhang H; Qiao G
    Thorac Cancer; 2020 Apr; 11(4):1094-1098. PubMed ID: 32077636
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
    Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated ferroptosis-related genes indicate potential clinical benefits for anti-PD-1/PD-L1 immunotherapy in lung adenocarcinoma.
    Zhou M; Zhang X; Li T; Chen Y
    J Clin Lab Anal; 2021 Dec; 35(12):e24086. PubMed ID: 34752672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete response induced by anti-PD-1-based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report.
    Xue W; Zhang T; Wang X; Duan J; Bi N
    J Clin Pharm Ther; 2020 Dec; 45(6):1511-1514. PubMed ID: 32893899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy.
    Zhang C; Yin K; Liu SY; Yan LX; Su J; Wu YL; Zhang XC; Zhong WZ; Yang XN
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
    Liang H; Xu Y; Chen M; Zhong W; Wang M; Zhao J
    Thorac Cancer; 2020 Apr; 11(4):1068-1075. PubMed ID: 32129934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
    Kodama H; Ibe T; Inoue R; Shimada T; Ishii H; Hamamoto Y
    Cancer Rep (Hoboken); 2020 Oct; 3(5):e1272. PubMed ID: 32783372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody.
    Saiki M; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Horiike A; Nishio M
    Lung Cancer; 2019 Jul; 133():4-9. PubMed ID: 31200826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
    Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
    de Vries R; Muller M; van der Noort V; Theelen WSME; Schouten RD; Hummelink K; Muller SH; Wolf-Lansdorf M; Dagelet JWF; Monkhorst K; Maitland-van der Zee AH; Baas P; Sterk PJ; van den Heuvel MM
    Ann Oncol; 2019 Oct; 30(10):1660-1666. PubMed ID: 31529107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
    Chen YM
    J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency.
    Yuan S; Hu X; Zhao Y; Wang Z
    Front Immunol; 2020; 11():563622. PubMed ID: 33240259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.